OncoVista Innovative Therapies Performance
| OVITDelisted Stock | USD 0.0001 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and OncoVista Innovative are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days OncoVista Innovative Therapies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward indicators, OncoVista Innovative is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
OncoVista |
OncoVista Innovative Relative Risk vs. Return Landscape
If you would invest 0.01 in OncoVista Innovative Therapies on October 24, 2025 and sell it today you would earn a total of 0.00 from holding OncoVista Innovative Therapies or generate 0.0% return on investment over 90 days. OncoVista Innovative Therapies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than OncoVista, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
OncoVista Innovative Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OncoVista Innovative's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as OncoVista Innovative Therapies, and traders can use it to determine the average amount a OncoVista Innovative's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| OVIT |
Based on monthly moving average OncoVista Innovative is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OncoVista Innovative by adding OncoVista Innovative to a well-diversified portfolio.
OncoVista Innovative Fundamentals Growth
OncoVista Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of OncoVista Innovative, and OncoVista Innovative fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OncoVista Pink Sheet performance.
| Return On Asset | -23.58 | |||
| Current Valuation | 852.92 K | |||
| Shares Outstanding | 23.56 M | |||
| Price To Earning | (0.12) X | |||
| Price To Book | 26.09 X | |||
| EBITDA | (3.4 M) | |||
| Cash And Equivalents | 61.27 K | |||
| Total Debt | 479.3 K | |||
| Book Value Per Share | (0.28) X | |||
| Cash Flow From Operations | (232.38 K) | |||
| Earnings Per Share | (0.15) X | |||
| Total Asset | 12.51 K | |||
| Retained Earnings | (27.6 M) | |||
| Current Asset | 61 K | |||
| Current Liabilities | 5.95 M | |||
About OncoVista Innovative Performance
Assessing OncoVista Innovative's fundamental ratios provides investors with valuable insights into OncoVista Innovative's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the OncoVista Innovative is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company was founded in 2004 and is based in San Antonio, Texas. ONCOVISTA INNOVATIVE operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about OncoVista Innovative performance evaluation
Checking the ongoing alerts about OncoVista Innovative for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for OncoVista Innovative help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OncoVista Innovative is not yet fully synchronised with the market data | |
| OncoVista Innovative has some characteristics of a very speculative penny stock | |
| OncoVista Innovative has a very high chance of going through financial distress in the upcoming years | |
| OncoVista Innovative Therapies currently holds 479.3 K in liabilities. OncoVista Innovative has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist OncoVista Innovative until it has trouble settling it off, either with new capital or with free cash flow. So, OncoVista Innovative's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OncoVista Innovative sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OncoVista to invest in growth at high rates of return. When we think about OncoVista Innovative's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| OncoVista Innovative Therapies currently holds about 61.27 K in cash with (232.38 K) of positive cash flow from operations. |
- Analyzing OncoVista Innovative's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OncoVista Innovative's stock is overvalued or undervalued compared to its peers.
- Examining OncoVista Innovative's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OncoVista Innovative's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OncoVista Innovative's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OncoVista Innovative's pink sheet. These opinions can provide insight into OncoVista Innovative's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in OncoVista Pink Sheet
If you are still planning to invest in OncoVista Innovative check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoVista Innovative's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |